Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy

Prodrugs are chemically modified drug molecules that are inactive before administration. After administration, they are converted in situ to parent drugs and induce the mechanism of action. The development of prodrugs has upgraded conventional drug treatments in terms of bioavailability, targeting,...

Full description

Saved in:
Bibliographic Details
Main Authors: Ding, Chendi, Chen, Chunbo, Zeng, Xiaowei, Chen, Hongzhong, Zhao, Yanli
Other Authors: School of Chemistry, Chemical Engineering and Biotechnology
Format: Article
Language:English
Published: 2023
Subjects:
Online Access:https://hdl.handle.net/10356/165552
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-165552
record_format dspace
spelling sg-ntu-dr.10356-1655522023-06-21T07:52:26Z Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy Ding, Chendi Chen, Chunbo Zeng, Xiaowei Chen, Hongzhong Zhao, Yanli School of Chemistry, Chemical Engineering and Biotechnology Science::Chemistry Biomedical Nanotechnology Cancer Therapy Prodrugs are chemically modified drug molecules that are inactive before administration. After administration, they are converted in situ to parent drugs and induce the mechanism of action. The development of prodrugs has upgraded conventional drug treatments in terms of bioavailability, targeting, and reduced side effects. Especially in cancer therapy, the application of prodrugs has achieved substantial therapeutic effects. From serendipitous discovery in the early stage to functional design with pertinence nowadays, the importance of prodrugs in drug design is self-evident. At present, studying stimuli-responsive activation mechanisms, regulating the stimuli intensity in vivo, and designing nanoscale prodrug formulations are the major strategies to promote the development of prodrugs. In this review, we provide an outlook of recent cutting-edge studies on stimuli-responsive prodrug nanosystems from these three aspects. We also discuss prospects and challenges in the future development of such prodrugs. National Research Foundation (NRF) Submitted/Accepted version This work was supported by the start-up fund (BS2021001) from Maoming People’s Hospital, the Guangdong Medical Science and Technology Research Fund (A2021213), the Programs Supported by Tianjin Key Laboratory of Biomedical Materials, the National Natural Science Foundation of China (32101065), and the Singapore National Research Foundation Investigatorship (NRF-NRFI2018-03). 2023-03-31T01:51:47Z 2023-03-31T01:51:47Z 2022 Journal Article Ding, C., Chen, C., Zeng, X., Chen, H. & Zhao, Y. (2022). Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy. ACS Nano, 16(9), 13513-13553. https://dx.doi.org/10.1021/acsnano.2c05379 1936-0851 https://hdl.handle.net/10356/165552 10.1021/acsnano.2c05379 9 16 13513 13553 en NRF-NRFI2018-03 ACS Nano This document is the Accepted Manuscript version of a Published Work that appeared in final form in ACS Nano, copyright © 2022 American Chemical Society, after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acsnano.2c05379. application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Science::Chemistry
Biomedical Nanotechnology
Cancer Therapy
spellingShingle Science::Chemistry
Biomedical Nanotechnology
Cancer Therapy
Ding, Chendi
Chen, Chunbo
Zeng, Xiaowei
Chen, Hongzhong
Zhao, Yanli
Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy
description Prodrugs are chemically modified drug molecules that are inactive before administration. After administration, they are converted in situ to parent drugs and induce the mechanism of action. The development of prodrugs has upgraded conventional drug treatments in terms of bioavailability, targeting, and reduced side effects. Especially in cancer therapy, the application of prodrugs has achieved substantial therapeutic effects. From serendipitous discovery in the early stage to functional design with pertinence nowadays, the importance of prodrugs in drug design is self-evident. At present, studying stimuli-responsive activation mechanisms, regulating the stimuli intensity in vivo, and designing nanoscale prodrug formulations are the major strategies to promote the development of prodrugs. In this review, we provide an outlook of recent cutting-edge studies on stimuli-responsive prodrug nanosystems from these three aspects. We also discuss prospects and challenges in the future development of such prodrugs.
author2 School of Chemistry, Chemical Engineering and Biotechnology
author_facet School of Chemistry, Chemical Engineering and Biotechnology
Ding, Chendi
Chen, Chunbo
Zeng, Xiaowei
Chen, Hongzhong
Zhao, Yanli
format Article
author Ding, Chendi
Chen, Chunbo
Zeng, Xiaowei
Chen, Hongzhong
Zhao, Yanli
author_sort Ding, Chendi
title Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy
title_short Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy
title_full Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy
title_fullStr Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy
title_full_unstemmed Emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy
title_sort emerging strategies in stimuli-responsive prodrug nanosystems for cancer therapy
publishDate 2023
url https://hdl.handle.net/10356/165552
_version_ 1772826297462947840